Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

165.74
Delayed Data
As of Mar 24
 -0.30 / -0.18%
Today’s Change
133.64
Today|||52-Week Range
184.21
+13.36%
Year-to-Date
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
Mar 24 / Zacks.com - Paid Partner Content
Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valean...
Mar 22 / Zacks.com - Paid Partner Content
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval
Mar 24 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
Mar 22 / Zacks.com - Paid Partner Content
Stock Market News for March 24, 2017
Mar 24 / Zacks.com - Paid Partner Content
4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
Mar 21 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Amgen, Walgreens Boots Allianc...
Mar 24 / Zacks.com - Paid Partner Content
3 Biotech Stocks That Are Broker Favorites
Mar 21 / Zacks.com - Paid Partner Content
Stock Research Reports for Amgen, Berkshire & Walgreens
Mar 23 / Zacks.com - Paid Partner Content
Biotech Bull Making a Comeback
Mar 21 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close166.04
Today’s open166.69
Day’s range165.08 - 166.93
Volume3,175,587
Average volume (3 months)3,866,618
Market cap$122.1B
Dividend yield2.78%
Data as of 3:59pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)+13.02%
Earnings growth (this year)+6.28%
Earnings growth (next 5 years)+6.55%
Revenue growth (last year)+6.31%
P/E ratio16.2
Price/Sales4.86
Price/Book4.10

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences+0.02+0.03%
BIIBBiogen-0.59-0.21%
ILMNIllumina Inc+2.89+1.72%
BIVVBioverativ Inc-0.17-0.34%
Data as of 3:59pm ET, 03/24/2017

Financials

Next reporting dateApril 25, 2017
EPS forecast (this quarter)$3.00
Annual revenue (last year)$22.7B
Annual profit (last year)$7.7B
Net profit margin34.04%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts


Search for Jobs